Patents Represented by Attorney Hal Gibson
-
Patent number: 8241641Abstract: Botulinum toxin, among other presynaptic neurotoxins is used for the treatment and prevention of migraine and other headaches associated with vascular disorders. Presynaptic neurotoxins are delivered focally, targeting the nerve endings of the trigeminal nerve, the occipital nerve and the intranasal terminals of the parasympathetic fibers originating in the Sphenopalatine ganglion. The administration preferably targets the extracranial nerve endings of the trigeminal nerve in the temporal area, the extracranial occipital nerve endings in the occipital area, and the intranasal terminals of the trigeminal nerve and parasympathetic fibers originating in the Sphenopalatine ganglion. The delivery is carried out by way of injection or topically.Type: GrantFiled: December 18, 2009Date of Patent: August 14, 2012Assignee: Allergan, Inc.Inventor: Andrew M. Blumenfeld
-
Patent number: 8216995Abstract: A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.Type: GrantFiled: October 31, 2007Date of Patent: July 10, 2012Assignee: Allergan, Inc.Inventors: Kei Roger Aoki, Michael W. Grayston, Steven R. Carlson, Judith M. Leon
-
Patent number: 8216591Abstract: This invention relates to the use of a composition comprising a polysaccharide and a botulinum toxin for reducing a skin wrinkle. In some embodiments, the polysaccharide comprises disaccharides. In some embodiments, the average molecular weight of a disaccharide unit of the polysaccharide is between about 345 D and about 1,000 D.Type: GrantFiled: October 9, 2006Date of Patent: July 10, 2012Assignee: Allergan, Inc.Inventor: Terrence J. Hunt
-
Patent number: 8168206Abstract: Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients.Type: GrantFiled: December 10, 2008Date of Patent: May 1, 2012Assignee: Allergan, Inc.Inventor: Terrence J. Hunt
-
Patent number: 8147848Abstract: Methods for prolongation of climax time in a patient in need thereof are presented, as are methods for treating premature ejaculation by local administration of a Clostridial neurotoxin, such a botulinum neurotoxin, to the patient, are provided.Type: GrantFiled: August 26, 2009Date of Patent: April 3, 2012Assignee: Allergan, Inc.Inventors: Gustavo M. Gaxiola, Ivan E. Aguilar, Gilberto P. Paz
-
Patent number: 8137677Abstract: A Clostridial toxin pharmaceutical composition comprising a Clostridial toxin, such as a botulinum toxin, wherein the Clostridial toxin present in the pharmaceutical composition is stabilized by a non-protein excipient such as a polyvinylpyrrolidone, a disaccharides, a trisaccharide, a polysaccharide, an alcohol, a metal, an amino acid, a surfactant and/or a polyethylene glycol.Type: GrantFiled: September 21, 2006Date of Patent: March 20, 2012Assignee: Allergan, Inc.Inventor: Terrence J. Hunt
-
Patent number: 8129139Abstract: Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.Type: GrantFiled: July 13, 2009Date of Patent: March 6, 2012Assignee: Allergan, Inc.Inventors: Jennifer L. Ton, Hemant A. Patel, Ronald C. Bates, Wajdie M. Ahmad
-
Patent number: 8105611Abstract: Methods of treating one or more autoimmune disorders include a step of administering a Clostridial neurotoxin, such as a botulinum toxin, to a patient that has an autoimmune disorder. In one aspect, a method includes a step of administering the neurotoxin to the thymus gland or near the thymus gland of the patient. In another aspect, a method includes a step of administering the neurotoxin in combination with administering a cytokine inhibitor to the patient. Compositions are also described.Type: GrantFiled: June 17, 2005Date of Patent: January 31, 2012Assignee: Allergan, Inc.Inventors: Kenneth L. Tong, Pamela D. Van Schaack
-
Patent number: 8071550Abstract: A method for treating uterine disorders, including hyperplasic, hypertonic, cystic and/or neoplastic uterine gland tissue by local administration of a botulinum toxin to or to the vicinity of the afflicted uterine tissue.Type: GrantFiled: March 3, 2003Date of Patent: December 6, 2011Assignee: Allergan, Inc.Inventor: Rhett M. Schiffman
-
Patent number: 8062643Abstract: The present invention related to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin.Type: GrantFiled: October 27, 2007Date of Patent: November 22, 2011Assignee: The Regents of the University of ColoradoInventor: Richard A Schmidt
-
Patent number: 8057808Abstract: Methods for treating obsessions and compulsions by local administration of a Clostridial toxin. The obsessions or compulsions can be eye poking, body rocking, finger biting, counting, checking and related disorders treated by low dose, intramuscular administration of a botulinum toxin.Type: GrantFiled: April 21, 2010Date of Patent: November 15, 2011Assignee: Allergen, Inc.Inventor: Alan H. Ackerman
-
Patent number: 8057807Abstract: The present invention related to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin.Type: GrantFiled: October 1, 2008Date of Patent: November 15, 2011Assignee: The Regents of the University of Colorado, a body corporateInventor: Richard A. Schmidt
-
Patent number: 8052980Abstract: A method for treating a patient suffering from arthritis and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxic component of neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.Type: GrantFiled: August 28, 2009Date of Patent: November 8, 2011Assignee: Allergan, Inc.Inventors: K. Roger Aoki, Michael W. Grayston, Steven R. Carlson, Judith M. Leon
-
Patent number: 8048423Abstract: Methods for treating skin disorders by local administration of a Clostridial toxin, such as a botulinum toxin, to a patient with a skin disorder.Type: GrantFiled: December 9, 2003Date of Patent: November 1, 2011Assignee: Allergan, Inc.Inventor: Eric R. First
-
Patent number: 8025889Abstract: Methods for treating conditions in an animal or human subject. The conditions may be pain, skeletal muscle conditions, smooth muscle conditions, glandular conditions and cosmetic conditions. The methods comprise the step of administering a Clostridium neurotoxin component or Clostridium neurotoxin component encoding DNA to the subject using a needleless syringe.Type: GrantFiled: December 19, 2008Date of Patent: September 27, 2011Assignee: Allergan, Inc.Inventor: Patricia S. Walker
-
Patent number: 8012716Abstract: Animal product free (APF) media and processes for the culture and fermentation of botulinum toxin producing Clostridium botulinum bacteria. The botulinum toxin obtained can be used for formulating and compounding botulinum toxin pharmaceutical compositions. The APF media can contain significantly reduced levels of meat or dairy by-products and use non-animal based products instead of the animal-derived products. Preferably, the APF media used are substantially free or free of animal derived products.Type: GrantFiled: July 10, 2009Date of Patent: September 6, 2011Assignee: Allergan, Inc.Inventors: Stephen Donovan, Ping Wang
-
Patent number: 8007828Abstract: Biodegradable neurotoxin implants and methods of making and using such implants are provided. Biodegradable neurotoxin implants include a neurotoxin, a biodegradable polymer component, and an acidity regulating component. The biodegradable polymer component is effective in controlling the release of the neurotoxin from the implant when the implant is located in a patient's body. The acidity regulating component is effective in maintaining a pH of the implant in a desired range that may be effective in stabilizing the neurotoxin as the implant biodegrades when the implant is located in a patient's body. In one embodiment, an implant includes a botulinum toxin, a biodegradable polymer, and either monomers from which a biodegradable polymer is derived or oligomers including monomeric units substantially identical to a monomer from which a biodegradable polymer is derived, or a combination of such monomers and oligomers. The oligomers and biodegradable polymer may be derived from a single type of monomer.Type: GrantFiled: October 9, 2009Date of Patent: August 30, 2011Assignee: Allergan, Inc.Inventors: Patrick M. Hughes, Orest Olejnik
-
Patent number: 8008044Abstract: Media and processes for the fermentation of Clostridium botulinum and obtaining a botulinum toxin for use in formulating botulinum toxin pharmaceutical compositions. The growth media can contain significantly reduced levels of meat or dairy by-products using non-animal based products to replace the animal-derived products. Preferably, the media used are substantially free of animal derived products.Type: GrantFiled: September 19, 2008Date of Patent: August 30, 2011Assignee: Allergan, Inc.Inventor: Stephen Donovan